Phase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomas

Investigational New Drugs

Volumn 18, Issue 3, 2000, Pages 253-259

  Chidiac, T ^a   Budd, G Thomas ^a,b   Pelley, R ^a   Sandstrom, K ^a   McLain, D ^a   Elson, P ^a   Crownover, R ^a   Marks, K ^a   Muschler, G ^a   Joyce, M ^a   Zehr, R ^a   Bukowski, R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ADULT; ADVANCED CANCER; AGE; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; DYSESTHESIA; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LEIOMYOSARCOMA; LEUKOPENIA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; DOXORUBICIN; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; SARCOMA;

EID: 0033879520     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006429907449     Document Type: Article

References (29)

1. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G: Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 11-18, 1973
2. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GW, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940-1948, 1977
3. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin chemotherapy - efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19-27, 1974
4. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JW, Falkson G, DeConti RC: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982
5. Borden EC, Amato DA, Edmonson JK, Ritch PS, Shiraki M: Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 66: 862-867, 1990
6. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993
7. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840-850, 1987
8. Baker LH, Frank J, Fine G, Balcerzalk SP, Stephens RL, Stuckey WJ, Rivkin S, Saiki J, Ward JH: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 5: 851-861, 1987
9. Mason M, Robinson W, Harmer C, Westbury G: Intra-arterial adriamycin, conventionally fractionated radiotherapy and conservative surgery for soft tissue sarcomas. Clin Oncol (R Coll Radiol) 4: 32-35, 1992
10. Didolkar MS, Kanter PW, Baffi RR, Schwartz HS, Lopez R: Comparison of regional versus systemic chemotherapy with adriamycin. Ann Surg 187: 332-336, 1978
11. Gabizon AA, Barenholz Y, Bialer M: Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10: 703-708, 1993
12. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenhoiz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994
13. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55-63, 1996
14. Alien TM, Hansen C, Martin F, Redemann C, Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066: 29-36, 1991
15. Hollander M, Wolfe D: Nonparametric Statistical Methods. New York, NY: John Wiley & Sons, Inc., 1973
16. Oudard S, Thierry A, Jorgensen TJ, Rahman A: Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28: 259-265, 1991
17. Thierry AR, Dritschilo A, Rahman A: Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun 187: 1098-1105, 1992
18. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711-716, 1998
19. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, Usakewicz J, Hainsworth JW, Martelo OJ, Omura G, Braun TJ: Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multiinstitutional phase II trial. J Clin Oncol 7: 1655-1659, 1989
20. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451, 1998
21. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785, 1995
22. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group, J Clin Oncol 16: 683-691, 1998
23. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial [see comments]. J Clin Oncol 15: 3185-3191, 1997
24. Muggia FM, Hainsworth JD, Jeffers S, Miller R, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993, 1997
25. Garcia AA, Kempf RA, Rogers M, Muggia FM: A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 9: 1131-1133, 1998
26. Skubitz K: A phase II trial of pegylated liposomal doxorubicin (Doxil) demonstrates activity in refractory sarcoma, mesothelioma, and head and neck cancer. Proc Am Soc Clin Oncol 18: 541a (abstract 2090), 1999
27. Toma S, Tucci A, Villani G, Carteni G, Palumbo R: Liposomal doxorubicin (CAELYX) in advanced pretreated soft tissue sarcomas (STS): a phase II trial of the Italian sarcoma group (ISG). Proc Am Soc Clin Oncol 18: 540a (abstract 2087), 1999
28. Judson I, Radford J, Blay J-Y, Van hoesel W, LeCesne A, van Oosterom A, Nielsen O, Camb C, Wall R, Harris M, Hermes C, Donate Di Paola E, Verweij J: A randomized Phase II trial of Caelyx/Doxil versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS) - an EORTC soft tissue and bone sarcoma group (STBS) trial. Proc Am Soc Clin Oncol 18: 541a (abstract 2089), 1999
29. Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF: Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15: 2111-2117, 1997